CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14

•Anti-CCR5 humanized monoclonal antibody restored CD8 counts in COVID patients.•Inversely correlated with decreases in plasma viral load (pVL) by day 14.•CCL5/RANTES up 3–5-fold in mild/moderate patients and >100-fold in critical ones.•First report of highly sensitive, quantitative pVL by ddPCR i...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	International journal of infectious diseases Ročník 103; s. 25 - 32
Hlavní autori:	Patterson, Bruce K., Seethamraju, Harish, Dhody, Kush, Corley, Michael J., Kazempour, Kazem, Lalezari, Jay, Pang, Alina P.S., Sugai, Christopher, Mahyari, Eisa, Francisco, Edgar B., Pise, Amruta, Rodrigues, Hallison, Wu, Helen L., Webb, Gabriela M., Park, Byung S., Kelly, Scott, Pourhassan, Nader, Lelic, Alina, Kdouh, Lama, Herrera, Monica, Hall, Eric, Bimber, Benjamin N., Plassmeyer, Matthew, Gupta, Raavi, Alpan, Oral, O’Halloran, Jane A., Mudd, Philip A., Akalin, Enver, Ndhlovu, Lishomwa C., Sacha, Jonah B.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Canada Elsevier Ltd 01.02.2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases Elsevier
Predmet:	Adult Aged CCR5 CCR5 Receptor Antagonists - therapeutic use CD8-Positive T-Lymphocytes - immunology COVID-19 COVID-19 - immunology COVID-19 - virology COVID-19 Drug Treatment Cytokines - blood Female Humans Immunotherapy Leronlimab Male Middle Aged Plasma viral load RNA, Viral - blood SARS-CoV-2 Time Factors COVID-19 Plasma viral load CCR5 Immunotherapy Leronlimab
ISSN:	1201-9712, 1878-3511, 1878-3511
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!